Monoclonal antibodies in treatment of non-small cell lung cancer

Abstract

Battling with various types of cancerous diseases has been one of the greatest areas of national and global medical endeavors in the late 20th and during the 21st centuries. The prime example of such endeavors was the invention of the method to produce monoclonal antibodies (mAbs) in the 1970s. A major advantage of using mAbs rather than other conventional medicine or polyclonal antiserum is the potential availability of almost infinite quantities of a specific monoclonal antibody directed toward a single epitope.